SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences.
- UBS Global Biopharma Conference
- Format: Fireside Chat and 1x1 meetings
- Fireside Chat Date: Tuesday, November 17, 2026
- Fireside Chat Time: 11:20 – 11:50 a.m. GMT
- Location: London, UK
- Jefferies Global Healthcare Conference
- Format: Fireside Chat and 1x1 meetings
- Fireside Chat Date: Wednesday, November 18, 2026
- Fireside Chat Time: 8:00 – 8:25 a.m. GMT
- Location: London, UK
The live and archived webcasts will be accessible from the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events and replays will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-november-302936871.html
SOURCE Nektar Therapeutics
